Evogene Reports Second Quarter 2025 Financial Results

About this update from Evogene Ltd.

[{"type":"text","content":"Conference call and webcast: today, August 19, 2025, 9:00 am ET","length":63,"tagName":"p","attribs":{}},{"type":"text","content":"Financial Highlights:","length":21,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The financial results for the first half of 2025 of Lavie Bio, a subsidiary of Evogene and the MicroBoost AI for Ag operations, are presented as a single-line item in Evogene's consolidated statements of profit and loss for the first half of 2025. Their results are included under the line titled - "Loss from operations held for sale, net". This accounting treatment follows the intention to sell the majority of Lavie Bio's activities and the MicroBoost AI for Ag as of June 30, 2025.","length":504,"tagName":"p"}]},{"val":[{"type":"text","content":"In the first half of 2025, total revenues amounted to approximately $3.2 million, compared to $2.3 million in the first half of 2024. The increase was primarily driven by higher seed sales generated by Casterra.","length":211,"tagName":"p"}]},{"val":[{"type":"text","content":"During the first half of 2025, Evogene implemented a cost reduction plan, most of which was completed by the end of the second quarter of 2025. The initial impact of these reductions is partially reflected in the first half results, with the full effect expected to be realized in the second half of 2025.","length":305,"tagName":"p"}]},{"val":[{"type":"text","content":"In the first half of 2025, total operating expenses, net were approximately $7.7 million compared to approximately $11.1 million in the first half of 2024. This decrease is mainly due to the decrease in Evogene's subsidiaries' activity.","length":244,"tagName":"p"}]},{"val":[{"type":"text","content":"As of the end of the first half of 2025, the company's cash and short-term bank deposits balance was approximately $11.7 million. This cash balance does not reflect the expected proceeds from the sale of Lavie Bio's assets and the MicroBoost AI for Ag tech-engine to ICL, completed in July 2025.","length":303,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1567,"olType":false},{"type":"text","content":"REHOVOT, Israel, Aug. 19, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology and chemistry company aiming to revolutionize...

More updates from Evogene Ltd.